3.98
-0.02 (-0.50%)
| Penutupan Terdahulu | 4.00 |
| Buka | 3.95 |
| Jumlah Dagangan | 21,790 |
| Purata Dagangan (3B) | 387,622 |
| Modal Pasaran | 7,594,154 |
| Harga / Pendapatan (P/E TTM) | 0.010 |
| Harga / Buku (P/B) | 0.500 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Aug 2025 - 18 Aug 2025 |
| EPS Cair (TTM) | -5.09 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.15% |
| Nisbah Semasa (MRQ) | 1.25 |
| Aliran Tunai Operasi (OCF TTM) | -16.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -12.46 M |
| Pulangan Atas Aset (ROA TTM) | -59.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -204.60% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | NuCana plc | Bercampur | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.83 |
|
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Institusi | 0.15% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Glass Jacobson Investment Advisors Llc | 30 Sep 2025 | 15,000 |
| Flagstone Financial Management | 30 Sep 2025 | 0 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |